| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | -178.39% | -346.09% | -312.57% | -446.79% | -157.09% | -681.82% |
| EBITDA Margin | -174.74% | -340.15% | -305.96% | -440.32% | -154.67% | -672.44% |
| Net Margin | -162.85% | -309.73% | -278.54% | -435.14% | -157.21% | -678.84% |
| Current Ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 13.10 |
| Quick Ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 13.10 |
| Debt / Equity | — | — | — | — | — | — |
| ROE | -29.35% | -65.31% | -40.20% | -43.36% | -16.89% | -1039.44% |
| ROA | -25.48% | -41.17% | -25.27% | -24.78% | -11.64% | -30.88% |
| Asset Turnover | 0.16 | 0.13 | 0.09 | 0.06 | 0.07 | 0.05 |
| Book Value / Share | 2.98 | 1.83 | 2.68 | 2.84 | 5.55 | 0.16 |
Tango Therapeutics Inc. is a biotechnology company focused on discovering and developing precision oncology therapies. The company applies synthetic lethality and target discovery approaches to identify cancer dependencies that can be addressed with medicines designed for specific tumor types. Its current pipeline centers on programs in oncology, including PRMT5 inhibitor candidates aimed at cancers such as pancreatic, lung, and brain tumors, along with research efforts tied to tumor suppressor gene loss and other genetically defined patient populations. Tango Therapeutics Inc. operates in the clinical-stage drug development segment, where its work contributes to the broader precision medicine market by advancing targeted approaches intended to improve cancer treatment specificity. The company is headquartered in Boston, Massachusetts, and is positioned within the life sciences sector as a developer of innovative therapeutic candidates for patients with high unmet medical need.